

## Inventera Pharmaceutical Inc.

Corporation	Inventera Pharmaceutical Inc.
○ Representative	Tae-Hyun Shin
○ Establishment year	2018
○ Specialized Field	MRI contrast agent
○ Address	SB Plaza 3F A1, 194-25, Osong Saengmyeong 1-ro, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do
○ Home page	- <a href="http://www.inventerapharm.com">http://www.inventerapharm.com</a>
○ Enterprise Brief Introduction	<p>- Inventera Pharmaceuticals Inc. is a bio tech company developing groundbreaking technologies, ranging from new materials and high-value therapeutics and diagnostics.</p> <p>- Established in November 2018, we received one of the most prestigious gov'n't research grants (TIPS program) from Ministry of SMEs and Startups (December, 2018). In 2020, we successfully raised series A fund (50 억won) from venture capitals and pharmaceutical companies.</p> <p>- We are now focusing on development of first-/best-in-class T1-MRI contrast agents. Our contrast agent is free from toxic gadolinium and can provide ~100 micrometer high-spatial-resolution MRI images.</p> <p>Key indications of our contrast agents are (i) cerebrocardiovascular and (ii) musculoskeletal, which are the largest segments of contrast agents market.</p> <p>- Musculoskeletal contrast agents (code name: INV-002) are approved for clinical phase I/IIa studies by the Ministry of Food and Drug Safety. Cerebrocardiovascular contrast agents (code name: INV-001) is in preclinical stage.</p>
○ Product and Pipeline Introduction	<p style="text-align: center;">“Renal clearable high-resolution T1-MRI contrast agents”</p> <ol style="list-style-type: none"> <li>1) Iron-based T1-MRI contrast agents (gadolinium-free)</li> <li>2) Long circulating pharmacokinetics enabling high-resolution scanning</li> <li>3) Thorough renal excretion capability</li> </ol> <hr/> <ol style="list-style-type: none"> <li>1) Code name INV-002 -Indication: Musculoskeletal system -Development stage: Clinical phase 1/2a (IND approved by the Ministry of Food and Drug Safety)</li> <li>2) Code name INV-001 -Indication: Cerebrovascular -Development stage: Preclinical</li> <li>3) Code name: INV-003R -Indication: Cerebrovascular (for research) -Development stage: Completed (currently used as research purpose contrast agents by researchers)</li> </ol>
○ Patent and Certification, Licensing, Thesis, Investment status, etc.	Patent: Republic of Korea No. 10-1991912 / Japan 6309542 Applied in the US, China, and Europe